{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T19:19:46Z","timestamp":1776885586748,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bmc.2025.118132","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:15:33Z","timestamp":1740586533000},"page":"118132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia"],"prefix":"10.1016","volume":"122","author":[{"given":"Jean-Philippe","family":"Surivet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bezen\u00e7on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Bouis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Gauvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Kiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chara","family":"Litou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Masse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary-Ann","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azely","family":"Mirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Uwe","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Rager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Ruetsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Alexander","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118132_b0005","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.sleep.2023.07.013","article-title":"Insomnia symptoms in adulthood. Prevalence and incidence over 25 years","volume":"109","author":"Klimt","year":"2023","journal-title":"Sleep Med"},{"key":"10.1016\/j.bmc.2025.118132_b0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia: prevalence, course, risk factors, and public health burden","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.bmc.2025.118132_b0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13311-012-0145-6","article-title":"Classification of sleep disorders","volume":"9","author":"Thorpy","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmc.2025.118132_b0020","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th Edition. 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.bmc.2025.118132_b0025","unstructured":"World Health Organization. ICD-11 revision. 2020. https:\/\/icd.who.int\/en."},{"key":"10.1016\/j.bmc.2025.118132_b0030","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.biopsych.2006.05.039","article-title":"Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication","volume":"60","author":"Roth","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bmc.2025.118132_b0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jpsychores.2010.03.010","article-title":"Nocturnal awakenings and difficulty resuming sleep: their burden in the European general population","volume":"69","author":"Ohayon","year":"2010","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.bmc.2025.118132_b0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.sleep.2009.11.004","article-title":"Using difficulty resuming sleep to define nocturnal awakenings","volume":"11","author":"Ohayon","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.bmc.2025.118132_b0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","article-title":"Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem","volume":"37","author":"Di Marco","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2025.118132_b0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2025.118132_b0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cmdc.201200025","article-title":"Discovery of [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxy]methyl-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties","volume":"7","author":"Coleman","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118132_b0060","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118132_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2025.118132_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000514961","article-title":"Twenty-Three Years of Hypocretins: The \u201cRosetta Stone\u201d of Sleep\/Arousal Circuits","volume":"45","author":"de Lecea","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.bmc.2025.118132_b0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bmc.2025.118132_b0080","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials","volume":"25","author":"Herring","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.bmc.2025.118132_b0085","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bmc.2025.118132_b0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2025.118132_b0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2025.118132_b0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"First approval","volume":"82","author":"Daridorexant","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118132_b0105","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/02698811231215415","article-title":"Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats","volume":"37","author":"Steiner","year":"2023","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bmc.2025.118132_b0110","unstructured":"Please refer to the following webpage: https:\/\/www.idorsia.us\/dam\/jcr:f97740c1-4fa7-43b3-9be1-69ae6296ef4d\/2023-citizens-petition-dora.pdf. Accessed 6 February 2025."},{"key":"10.1016\/j.bmc.2025.118132_b0115","first-page":"1277","article-title":"Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings","volume":"31","author":"Roth","year":"2008","journal-title":"Sleep"},{"key":"10.1016\/j.bmc.2025.118132_b0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5665\/sleep.2370","article-title":"Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study","volume":"36","author":"Roth","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/j.bmc.2025.118132_b0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hup.884","article-title":"Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate","volume":"23","author":"Roth","year":"2008","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.bmc.2025.118132_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6614","article-title":"Effect of suvorexant vs placebo on total daytime sleep hours in shift workers: a randomized clinical trial","volume":"3","author":"Zeitzer","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmc.2025.118132_b0135","doi-asserted-by":"crossref","first-page":"115489","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118132_b0140","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bmc.2025.118132_b0145","doi-asserted-by":"crossref","first-page":"117892","DOI":"10.1016\/j.bmc.2024.117892","article-title":"Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs","volume":"112","author":"Surivet","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118132_b0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118132_b0155","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/tx0496791","article-title":"Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites","volume":"18","author":"Gan","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2025.118132_b0160","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","article-title":"Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration","volume":"108","author":"Feng","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2025.118132_b0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40268-024-00456-8","article-title":"Effect of daridorexant on the pharmacokinetics of midazolam, and on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects","volume":"24","author":"Zenklusen","year":"2024","journal-title":"Drugs RD"},{"key":"10.1016\/j.bmc.2025.118132_b0170","unstructured":"Animal experiments were performed in accordance with Swiss Animal Protection Laws and the guidelines of the Basel-Landschaft Cantonal Veterinary Office."},{"key":"10.1016\/j.bmc.2025.118132_b0175","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1124\/dmd.109.028860","article-title":"Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins","volume":"37","author":"Usui","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2025.118132_b0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.vascn.2004.11.006","article-title":"A semi-automated method for measuring the potential for protein covalent binding in drug discovery","volume":"52","author":"Day","year":"2005","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.bmc.2025.118132_b0185","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1021\/tx300091x","article-title":"In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs","volume":"25","author":"Thompson","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2025.118132_b0190","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2025.118132_b0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.xphs.2024.08.029","article-title":"Amorphous solubility advantage: theoretical considerations, experimental methods, and contemporary relevance","volume":"114","author":"Ueda","year":"2025","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2025.118132_b0200","doi-asserted-by":"crossref","first-page":"118862","DOI":"10.1016\/j.ijpharm.2019.118862","article-title":"Comparison of induction methods for supersaturation: pH shift versus solvent shift","volume":"573","author":"Plum","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2025.118132_b0205","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s11095-023-03532-x","article-title":"Optimisation of pharmaceutical cocrystal dissolution performance through a synergistic precipitation inhibition","volume":"40","author":"Shi","year":"2023","journal-title":"Pharmaceut Res"},{"key":"10.1016\/j.bmc.2025.118132_b0210","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1021\/cg9001187","article-title":"Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility","volume":"9","author":"Bethune","year":"2009","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.bmc.2025.118132_b0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.xphs.2017.10.033","article-title":"Understanding the differences between cocrystal and salt aqueous solubilities","volume":"107","author":"Cavanagh","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2025.118132_b0220","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1021\/mp400426f","article-title":"Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy","volume":"10","author":"Mathias","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2025.118132_b0225","unstructured":"Solubility values for DORA 31 and its cocrystals were determined under equilibrium conditions. pH profiles were extrapolated using Henderson-Hasselbalch equations and equations described in ref. 43. These solubility curves provide insight into the supersaturation potential, illustrating that both cocrystals are thermodynamically unstable over the whole biorelevant pH range, leading to dissociation and releasing DORA 31 into a supersaturated state."},{"key":"10.1016\/j.bmc.2025.118132_b0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/acs.oprd.8b00349","article-title":"Highly selective synthesis of 2-(2H-1,2,3-triazol-2-yl)benzoic acids","volume":"23","author":"Roth","year":"2019","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2025.118132_b0235","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/jo960057x","article-title":"Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures","volume":"61","author":"Abdel-Magid","year":"1996","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2025.118132_b0240","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/cr00039a007","article-title":"Palladium-catalyzed cross-coupling reactions of organoboron compounds","volume":"95","author":"Miyaura","year":"1995","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2025.118132_b0245","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/acs.oprd.2c00331","article-title":"Development of a scalable route for a key benzothiazole building block via a pd-catalyzed migita coupling with a nonsmelly thiol surrogate","volume":"26","author":"Sch\u00e4fer","year":"2022","journal-title":"Org Process Res Dev"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:40:03Z","timestamp":1744360803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S0968089625000732"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118132","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118132"}}